FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
61 letters match. Newest first.
-
DrugsUSV Private Limited
FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.
High risk -
DrugsNorthland Nuclear Medicine, LLC
FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.
High risk -
DrugsBaxter International Inc.
Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.
High risk -
DrugsHanlim Pharm Co., Ltd.
FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.
High risk -
DrugsSCA Pharmaceuticals, LLC
SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.
High risk -
AnimalSciarra Aeromed, Inc.
Sciarra Aeromed's purportedly sterile veterinary drug was contaminated and made under insanitary conditions, FDA says.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharmacy
FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.
High risk -
DrugsBausch & Lomb Inc.
FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.
High risk -
DrugsJabil Inc.
FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.
High risk -
DrugsReliance Life Sciences Private Limited
FDA warned India's Reliance Life Sciences over falsified microbiology records and aseptic failures in sterile drug production, prompting a recall.
High risk -
DrugsEugia Pharma Specialities Limited
FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.
High risk -
DrugsK.C. Pharmaceuticals, Inc.
FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.
High risk -
DrugsFareva Amboise
FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.
High risk -
DrugsInternational Medication Systems Limited
FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.
High risk -
DrugsExcelvision - Fareva
FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.
High risk -
DrugsWizcure Pharmaa Private Limited
FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.
High risk -
DrugsHuons Co., Ltd.
FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.
High risk -
DrugsJubilant HollisterStier General Partnership
FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.
High risk -
DrugsPharmathen International S.A.
FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
High risk -
DrugsFagron BV
FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.
High risk -
DrugsPar Health USA, LLC & Endo USA, Inc.
FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.
High risk -
DrugsNew Life Pharma LLC
New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.
High risk -
DrugsApothecary Pharma, LLC
FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.
High risk -
DrugsBoothwyn Pharmacy, LLC
Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.
High risk -
DrugsRevive Rx LLC dba Revive Rx Pharmacy
FDA warns Revive Rx Pharmacy over insanitary production of sterile compounded drugs, citing contamination risks.
High risk -
DrugsPQ Pharmacy, LLC
FDA warns PQ Pharmacy, a Florida sterile drug compounder, that its products were made under unsafe conditions.
High risk -
DrugsWells Pharma of Houston, LLC
FDA warns Wells Pharma of Houston over sterile compounded drugs made under insanitary conditions.
High risk -
DrugsBRS Analytical Services, LLC
BRS Analytical Services, LLC made sterile OTC drugs in an unsuitable aseptic facility and recalled them over sterility assurance.
High risk -
DrugsSomerset Therapeutics Private Limited
FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.
High risk -
AnimalBoothwyn Pharmacy LLC
FDA warns Boothwyn Pharmacy over unapproved compounded animal drugs and falsified endotoxin records.
High risk -
DrugsDaewoo Pharmaceutical Co., Ltd.
FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.
High risk -
DrugsExcelvision Fareva
Excelvision Fareva, a sterile drug manufacturer, was cited for inadequate mold/black-speck complaint investigations and aseptic contamination controls.
High risk -
DrugsOSRX, Inc.
OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.
High risk -
DrugsTailstorm Health Inc. dba Medivant Health
Tailstorm Health (Medivant Health) sterile compounded drugs had insanitary conditions and current good manufacturing practice failures, prompting a bevacizumab recall.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharma
FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.
High risk -
DrugsRight Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals
FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.
High risk -
DrugsProRx, LLC
FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.
High risk -
DrugsIndoco Remedies Limited
FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.
High risk -
DrugsOmni Lens Pvt. Ltd.
FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.
High risk -
DrugsStokes Healthcare Inc. dba Epicur Pharma
Sterile compounding facility Epicur Pharma made drugs under insanitary conditions and with serious quality failures, FDA says.
High risk -
BiologicsHemarus LLC
Hemarus LLC failed blood-product manufacturing rules, including unapproved donor reinstatement and records signed when physician absent.
High risk -
DrugsZydus Lifesciences Limited
FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.
High risk -
DrugsEugia Pharma Specialities Limited
FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.
High risk -
DrugsBrassica Pharma Pvt. Ltd.
FDA warns Brassica Pharma over fabricated sterility and environmental data and poor aseptic controls for sterile drugs.
High risk -
DrugsJiangsu Hengrui Pharmaceuticals Co., Ltd.
FDA found data integrity failures and inadequate sterile manufacturing controls at Jiangsu Hengrui Pharmaceuticals' drug facility.
High risk -
DrugsNorthern VA Compounders PLLC, dba Akina Pharmacy
FDA warns Akina Pharmacy over unsafe production of compounded drugs and sterility risks.
High risk -
DrugsAmman Pharmaceutical Industries
FDA warned Amman Pharmaceutical Industries after a 2023 inspection found sterile drug manufacturing and data integrity failures.
High risk -
DrugsMadhu Instruments Private Limited
FDA cites Madhu Instruments in New Delhi for insanitary conditions in sterile drug manufacturing and places it on import alert.
High risk -
DrugsIntas Pharmaceuticals Limited
FDA cited Intas Pharmaceuticals for CGMP violations, including manipulated visual inspection records and inadequate sterile-drug controls.
High risk -
DrugsSouthern Tier Home Infusion, Inc. dba Pharmacy Innovations
FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.
High risk